WX [WuXi PharmaTech (Cayman)] 20-F: WuXi PharmaTech (Cayman) Inc. Page INTRODUCTION 1 2

Ticker: WX, Company: WuXi PharmaTech (Cayman) Inc., Type: 20-F, Date: 2015-04-15, XBRL Interactive Financials
Original SEC Filing: Click here


Webplus: WX/20150415/20-F/1/000.htm SEC Original: d796029d20f.htm
WuXi PharmaTech (Cayman) Inc. Page INTRODUCTION 1 2 PART I. ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS 3 ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE 3 ITEM 3. KEY INFORMATION 3 ITEM 4. INFORMATION ON THE COMPANY 27 ITEM 4A. UNRESOLVED STAFF COMMENTS 49 ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS 49 ITEM 6. DIRECTORS, SENIOR MANAGEMENT




Webplus: WX/20150415/20-F/2_EX-4.22/000.htm SEC Original: d796029dex422.htm
Execution Version Dated 16 February 2015 WUXI PHARMATECH (CAYMAN) INC. AS BORROWER WUXI APPTEC HOLDING COMPANY, INC. WUXI APPTEC, INC. WUXI APPTEC (BVI) INC. WUXI APPTEC (HONG KONG) LIMITED AS ORIGINAL GUARANTORS CITIGROUP GLOBAL MARKETS ASIA LIMITED AS COORDINATING ARRANGER AND CITICORP INTERNATIONAL LIMITED AS AGENT FACILITY AGREEMENT FOR US$165,000,000 SENIOR TERM AND REVOLVING LOAN FACILITY CONTENTS Clause Page 1.




Webplus: WX/20150415/20-F/3_EX-8.1/000.htm SEC Original: d796029dex81.htm
LIST OF SUBSIDIARIES Name Abbreviation Place of Incorporation WuXi AppTec (BVI) Inc. WXAT BVI British Virgin Islands WuXi AppTec Co., Ltd. WXAT PRC WuXi AppTec (Shanghai) Co., Ltd. WASH PRC Shanghai SynTheAll Pharmaceutical Co., Ltd. STA PRC WuXi AppTec (Suzhou) Co., Ltd. WASZ PRC WuXi AppTec (Tianjin) Co., Ltd. WATJ PRC WuXi AppTec Holding Company, Inc. AppTec Holding WuXi AppTec,




Webplus: WX/20150415/20-F/4_EX-12.1/000.htm SEC Original: d796029dex121.htm
Certification by the Chief Executive Officer I, Ge Li, certify that: 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered




Webplus: WX/20150415/20-F/5_EX-12.2/000.htm SEC Original: d796029dex122.htm
Certification by the Chief Financial Officer I, Edward Hu, certify that: 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered




Webplus: WX/20150415/20-F/6_EX-13.1/000.htm SEC Original: d796029dex131.htm
Section 906 of the Sarbanes-Oxley Act of 2002 Ge Li Chief Executive Officer EX-13.1 6 d796029dex131.htm EX-13.1




Webplus: WX/20150415/20-F/7_EX-13.2/000.htm SEC Original: d796029dex132.htm
Certification by the Chief Financial Officer Edward Hu Chief Financial Officer EX-13.2 7 d796029dex132.htm EX-13.2




Webplus: WX/20150415/20-F/8_EX-23.1/000.htm SEC Original: d796029dex231.htm
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in this Registration Statement No. 333-182917 on Form S-8 of our reports dated April 15, 2015, relating to the consolidated financial statements and financial statement schedule of Wuxi PharmaTech (Cayman) Inc. and its subsidiaries, and the effectiveness of Wuxi PharmaTech (Cayman) Inc. and its subsidiaries’ internal



Company Information:

Ticker: WX, Company: WuXi PharmaTech (Cayman) Inc., Type: 20-F, Date: 2015-04-15, XBRL Interactive FinancialsCIK: 0001403132, Location: F4, SIC: 2834, SIC Desc: PHARMACEUTICAL PREPARATIONS
Business Phone & Address:
288 FUTE ZHONG ROAD
SHANGHAI 200131

Home Page Forums

By | 2016-03-24T02:48:18+00:00 April 15th, 2015|Categories: Chinese Stocks, Webplus ver, WX|Tags: , , , , , |0 Comments

About the Author:

Leave A Comment

Skip to toolbar